Lupin Limited

Lupin Limited

Lupin Limited has received an Establishment Inspection Report (EIR) from the US FDA for its Somerset facility with a satisfactory Voluntary Action Indicated (VAI) classification.

Lupin Limited

Lupin Limited has completed the acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. (MPPI) and MPPI has completed the buy-back of 61,118 shares from two existing shareholders.

Lupin Limited

Lupin Limited has announced that the European Medicines Agency (EMA) has approved a change to the terms of marketing authorization for NaMuscla, a treatment for myotonia symptoms in non-dystrophic myotonic disorders, with new dosage strengths and expanded pediatric indication.

Lupin Limited

Lupin Limited has informed the Exchange regarding the grant of 65,251 stock options to its employees and subsidiaries, with an exercise price of ₹ 2.00 per option and a vesting period of three years.

Lupin Limited

Lupin Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Lupin Limited

Lupin Limited has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Enzalutamide Tablets, providing alternative dosing options for healthcare providers and patients.

Lupin Limited

Lupin Limited has announced the grant of 1,567,591 stock options to its employees and subsidiaries under the Lupin Employees Stock Option Scheme 2025. Each option provides the right to subscribe to one equity share at an exercise price of ₹2.00. These options will vest over a three-year period, commencing one year after the effective grant date of July 01, 2026, subject to specific performance conditions. This initiative aims to incentivize and retain key talent within the organization.